| 23.66 -0.44 (-1.83%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.95  |
1-year : | 30.71 |
| Resists | First : | 24.79 |
Second : | 26.29 |
| Pivot price | 24.29 |
|||
| Supports | First : | 22.35 |
Second : | 18.59 |
| MAs | MA(5) : | 24.36 |
MA(20) : | 24.18 |
| MA(100) : | 29.48 |
MA(250) : | 30.88  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 53.2 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 48.45 | Low : | 17.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AAPG ] has closed above bottom band by 23.9%. Bollinger Bands are 46.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.45 - 24.6 | 24.6 - 24.71 |
| Low: | 22.02 - 22.2 | 22.2 - 22.34 |
| Close: | 23.41 - 23.69 | 23.69 - 23.9 |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Mon, 02 Mar 2026
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? - MarketBeat
Fri, 27 Feb 2026
AAPG Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 25 Feb 2026
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Significant Drop in Short Interest - MarketBeat
Mon, 23 Feb 2026
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks
Mon, 23 Feb 2026
Biotech Ascentage Pharma sets talks at three investor conferences - Stock Titan
Tue, 17 Feb 2026
Ascentage Pharma Group (AAPG) Stock Analysis: Biotech Giant with 91.92% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | -296.8 % |
| Operating Margin | -237.1 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | -159.7 % |
| Qtrly Rev. Growth | -71.6 % |
| Gross Profit (p.s.) | 3.81 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | -11.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -189 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -11.27 |
| PEG Ratio | 0 |
| Price to Book value | 84.5 |
| Price to Sales | 5.63 |
| Price to Cash Flow | -11.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|